{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:29:03Z","timestamp":1771633743388,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:00:00Z","timestamp":1539043200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Vancomycin-resistant enterococcus (VRE) causes substantial health care\u2013associated infection with increasing reports of resistance to daptomycin or linezolid. We conducted a case\u2013control study reporting 81 cases of daptomycin and linezolid\u2013nonsusceptible VRE (DLVRE), a resistance pattern not previously reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed VRE isolates from June 2010 through June 2015 for nonsusceptibility to both daptomycin (minimum inhibitory concentration [MIC] &amp;gt; 4) and linezolid (MIC \u2265 4). We matched cases by year to control patients with VRE susceptible to both daptomycin and linezolid and performed retrospective chart review to gather risk factor and outcome data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 81 DLVRE cases. Resistance to both daptomycin and linezolid was more common than resistance to either agent individually. Compared with susceptible VRE, DLVRE was more likely to present as bacteremia without focus (P &amp;lt; 0.01), with DLVRE patients more likely to be immune suppressed (P = .04), to be neutropenic (P = .03), or to have had an invasive procedure in the prior 30 days (P = .04). Any antibiotic exposure over the prior 30 days conferred a 4-fold increased risk for DLVRE (odds ratio [OR], 4.25; 95% confidence interval [CI], 1.43\u221212.63; P = .01); multivariate analysis implicated daptomycin days of therapy (DOT) over the past year as a specific risk factor (OR, 1.10; 95% CI, 1.01\u22121.19; P = .03). DLVRE cases had longer hospitalizations (P = .04) but no increased risk for in-hospital death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>DLVRE is an emerging multidrug-resistant pathogen associated with immune suppression, neutropenia, and recent invasive procedure. Prior antibiotic exposure, specifically daptomycin exposure, confers risk for acquisition of DLVRE.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ofid\/ofy185","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T10:42:46Z","timestamp":1539081766000},"source":"Crossref","is-referenced-by-count":25,"title":["Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid\u2013Nonsusceptible Vancomycin-Resistant Enterococcus"],"prefix":"10.1093","volume":"5","author":[{"given":"Matthew H","family":"Greene","sequence":"first","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan D","family":"Harris","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitney J","family":"Nesbitt","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marley L","family":"Watson","sequence":"additional","affiliation":[{"name":"Emory Healthcare, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patty W","family":"Wright","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R","family":"Talbot","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George E","family":"Nelson","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,9]]},"reference":[{"key":"2020081004182856000_CIT0001","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4065\/81.4.529","article-title":"Vancomycin-resistant enterococci: colonization, infection, detection, and treatment","volume":"81","author":"Zirakzadeh","year":"2006","journal-title":"Mayo Clinic Proc"},{"key":"2020081004182856000_CIT0002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/430909","article-title":"Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis","volume":"41","author":"DiazGranados","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020081004182856000_CIT0003","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1086\/423841","article-title":"Antimicrobial resistance to linezolid","volume":"39","author":"Meka","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020081004182856000_CIT0004","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00030-13","article-title":"A current perspective on daptomycin for the clinical microbiologist","volume":"26","author":"Humphries","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2020081004182856000_CIT0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.diagmicrobio.2009.06.016","article-title":"Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007\u20132008)","volume":"65","author":"Sader","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004182856000_CIT0006","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.02803-15","article-title":"Linezolid surveillance results for the United States (LEADER surveillance program 2014)","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004182856000_CIT0007","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/jac\/dkw052","article-title":"Surveillance for linezolid resistance via the Zyvox\u00ae Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates","volume":"71","author":"Mendes","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020081004182856000_CIT0008","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijantimicag.2014.01.018","article-title":"Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012)","volume":"43","author":"Sader","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2020081004182856000_CIT0009","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1086\/659152","article-title":"Emergence of daptomycin-resistant VRE: experience of a single institution","volume":"32","author":"Kamboj","year":"2011","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020081004182856000_CIT0010","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1086\/344177","article-title":"Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium","volume":"35","author":"Pai","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020081004182856000_CIT0011","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3201\/eid1307.070019","article-title":"Response to emerging infection leading to outbreak of linezolid-resistant enterococci","volume":"13","author":"Kainer","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"2020081004182856000_CIT0012","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1086\/523276","article-title":"Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus","volume":"28","author":"Pogue","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020081004182856000_CIT0013","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ajic.2011.11.005","article-title":"Risk factors associated with linezolid-nonsusceptible enterococcal infections","volume":"40","author":"McGregor","year":"2012","journal-title":"Am J Infect Control"},{"key":"2020081004182856000_CIT0014","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.diagmicrobio.2012.05.025","article-title":"Risk factors and outcomes associated with vancomycin-resistant Enterococcus infections with reduced susceptibilities to linezolid","volume":"74","author":"Santayana","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004182856000_CIT0015","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.ajic.2012.06.009","article-title":"Predictors and outcomes of linezolid-resistant vancomycin-resistant Enterococcus: a case-case-control study","volume":"40","author":"Hayakawa","year":"2012","journal-title":"Am J Infect Control"},{"key":"2020081004182856000_CIT0016","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1086\/668438","article-title":"Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycin","volume":"33","author":"Judge","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020081004182856000_CIT0017","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/jac\/dkt117","article-title":"Evolution of high-level daptomycin resistance in Enterococcus faecium during daptomycin therapy is associated with limited mutations in the bacterial genome","volume":"68","author":"Kelesidis","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020081004182856000_CIT0018","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1128\/AAC.05918-11","article-title":"Case-control study comparing de novo and daptomycin-exposed daptomycin-nonsusceptible Enterococcus infections","volume":"56","author":"Kelesidis","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004182856000_CIT0019","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1128\/AAC.02683-14","article-title":"Identification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004182856000_CIT0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/mdr.2009.0045","article-title":"Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolates","volume":"15","author":"Mendes","year":"2009","journal-title":"Microb Drug Resist"},{"key":"2020081004182856000_CIT0021","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2020081004182856000_CIT0022","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1128\/AAC.00509-12","article-title":"Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints","volume":"56","author":"Munita","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004182856000_CIT0023","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1128\/AAC.02686-14","article-title":"Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs","volume":"58","author":"Diaz","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004182856000_CIT0024","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/infdis\/jiu602","article-title":"A liaR deletion restores susceptibility to daptomycin and antimicrobial peptides in multidrug-resistant Enterococcus faecalis","volume":"211","author":"Reyes","year":"2015","journal-title":"J Infect Dis"},{"key":"2020081004182856000_CIT0025","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJMoa1011138","article-title":"Genetic basis for in vivo daptomycin resistance in enterococci","volume":"365","author":"Arias","year":"2011","journal-title":"N Engl J Med"},{"key":"2020081004182856000_CIT0026","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1128\/AAC.01073-15","article-title":"Deletion of liaR reverses daptomycin resistance in Enterococcus faecium independent of the genetic background","volume":"59","author":"Panesso","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004182856000_CIT0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.04.002","article-title":"Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms","volume":"17","author":"Mendes","year":"2014","journal-title":"Drug Resist Updat"},{"key":"2020081004182856000_CIT0028","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0732-8893(03)00153-6","article-title":"Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs","volume":"47","author":"Ruggero","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004182856000_CIT0029","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM200203143461121","article-title":"Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium","volume":"346","author":"Herrero","year":"2002","journal-title":"N Engl J Med"},{"key":"2020081004182856000_CIT0030","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1086\/513876","article-title":"Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo","volume":"195","author":"Bourgeois-Nicolaos","year":"2007","journal-title":"J Infect Dis"},{"key":"2020081004182856000_CIT0031","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(00)04376-2","article-title":"Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid","volume":"357","author":"Gonzales","year":"2001","journal-title":"Lancet"},{"key":"2020081004182856000_CIT0032","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0732-8893(01)00333-9","article-title":"Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program","volume":"42","author":"Jones","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004182856000_CIT0033","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1128\/AAC.46.10.3334-3336.2002","article-title":"Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis","volume":"46","author":"Marshall","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004182856000_CIT0034","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1128\/AAC.45.7.2154-2156.2001","article-title":"Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci","volume":"45","author":"Prystowsky","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004182856000_CIT0035","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/cid\/ciw173","article-title":"Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint","volume":"62","author":"Shukla","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020081004182856000_CIT0036","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/318702","article-title":"Arthralgias and myalgias related to quinupristin-dalfopristin administration","volume":"32","author":"Olsen","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020081004182856000_CIT0037","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/cid\/cis270","article-title":"Excess deaths associated with tigecycline after approval based on noninferiority trials","volume":"54","author":"Prasad","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020081004182856000_CIT0038","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1128\/AAC.05077-14","article-title":"In vitro activity of daptomycin in combination with \u03b2-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci","volume":"59","author":"Hindler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004182856000_CIT0039","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/jac\/dkv007","article-title":"\u03b2-lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium","volume":"70","author":"Smith","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020081004182856000_CIT0040","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1128\/AAC.00053-15","article-title":"\u03b2-lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic\/pharmacodynamic models","volume":"59","author":"Smith","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/10\/ofy185\/33577676\/ofy185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/10\/ofy185\/33577676\/ofy185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T17:08:41Z","timestamp":1662224921000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofy185\/5123973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofy185","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,10,1]]},"article-number":"ofy185"}}